Drug
Tetomilast clinical trials
Also written OPC-6535.
- studies test it
- 8
- open now
- 0
- in phase 3
- 4
- first study started
- 2003
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
8 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2003 | 2 |
| 2004 | 1 |
| 2006 | 2 |
| 2009 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 5
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 0
Otsuka Pharmaceutical Co., Ltd. (4) · Otsuka Pharmaceutical Development & Commercialization, Inc. (4)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses tetomilast is read from its arms, and is right about nine times in ten.
Testing it · 8
- To Investigate the Efficacy and Safety of OPC-6535 in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedPhase 2Otsuka Pharmaceutical Co., Ltd.NCT00917150Written as tetomilast (OPC-6535)
- A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative ColitisTerminatedPhase 2Otsuka Pharmaceutical Co., Ltd.NCT00317356Written as OPC-6535(Tetomilast)
- A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's DiseaseCompletedPhase 2/3Otsuka Pharmaceutical Co., Ltd.NCT00989573Written as OPC-6535
- A Dose-finding Study of OPC-6535 in Patients With Active Crohn's DiseaseTerminatedPhase 2Otsuka Pharmaceutical Co., Ltd.NCT00317369Written as OPC-6535(Tetomilast)
- Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With EmphysemaTerminatedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT00874497Written as tetomilast
- FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative ColitisCompletedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT00064441Written as OPC-6535 Tablets (drug)
- FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative ColitisCompletedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT00064454Written as OPC-6535 Tablets (drug)
- CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) RemissionCompletedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT00092508Written as OPC-6535
Codes
What other systems call tetomilast · ClinicalTrials.gg INT004026
- MeSH (NLM) C108965tetomilastOne source NLM
- UNII (FDA) S6RXB5KF56TETOMILASTConfirmed FDA, NLM, Wikidata
- Wikidata Q27095582tetomilastConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C90922TetomilastOne source FDA
- DrugBank DB05298One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C108965 | tetomilast | One source NLM |
| UNII (FDA) | S6RXB5KF56 | TETOMILAST | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27095582 | tetomilast | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C90922 | Tetomilast | One source FDA |
| DrugBank | DB05298 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.